Breast cancer is the most common cancer in women.
It is estimated that breast cancer is responsible for over 500,000 deaths each year worldwide.
There are an estimated 1.7 million news of breast cancer diagnosed each year.
TNBC is a histological subtype of breast cancer that is aggressive, with an overall poor prognosis due to a lack of effective treatment options.
Triple Negative Breast Cancer
Despite marked advancement in breast cancer treatment and detection, 20-30% of breast cancer patients relapse, often with cancer found in distal organs. Aggressive forms of breast cancer that lack the markers estrogen, progesterone and HER2 (triple negative breast cancer, TNBC) account for 15-20% of all breast cancers in the US. These cancers disproportionally affect young woman and minorities and have higher rates of relapse and poorer outcomes than other forms of breast cancer.
TNBC are resistant to targeted therapies use to treat other types of breast cancer. TNBC contain a high frequency of cancer stems cells. While these cells represent a small fraction of cancer cells found in the tumor, they are responsible for most of the cancer spread and relapse. Therefore, effective treatments for TNBC must also target cancer stem cells.
The Agilvax Solution for Breast Cancer
Agilvax is developing AX09 as the lead immunotherapy candidate for the treatment of aggressive forms of breast cancer. Immunization with AX09 elicits antibodies targeting breast cancer stem cells, a key cellular reservoir for relapse, metastatic progression and therapeutic resistance. In preclinical models, AX09 treatment results in a significant reduction in metastatic lesions and has increased efficacy in combination with breast cancer chemotherapeutic agents. Agilvax is further refining AX09 to enhance its efficacy for the treatment of breast cancer.